We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pivotal trials for β-secretase inhibitors in Alzheimer's.
- Authors
Sheridan, Cormac
- Abstract
The article focuses on pivotal phase 2/3 trial of β-secretase cleaving enzyme (BACE) inhibitor AZD3293 for Alzheimer's diseases by several pharmaceutical firms such as Eli Lilly and AstraZeneca. Topics discussed include indication of role for amyloid precursor protein (APP) processing in Alzheimer's, effectiveness of Solanezumab drug in reducing cognitive decline, and views of Bart De Strooper, of the Flanders Institute for Biotechnology in Belgium, on being careful with drug targets.
- Subjects
CLINICAL drug trials; ALZHEIMER'S disease; ELI Lilly &; Co.; ASTRAZENECA PLC; AMYLOID beta-protein precursor; DRUG efficacy; DE Strooper, Bart
- Publication
Nature Biotechnology, 2015, Vol 33, Issue 2, p115
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0215-115